猫疱疹病毒载体狂犬病疫苗在猫中的双重保护
在中国,猫引起约5%的人狂犬病病例,但尚无猫专用狂犬病疫苗。本研究以猫疱疹病毒1型(FHV-1)为载体,缺失gI/E基因并插入狂犬病病毒(RABV)BD06株糖蛋白(G)基因,构建重组疫苗FHV-RVG;猫经鼻接种1 ml 10^6.5 TCID50后,所有接种猫均产生抗FHV-1和RABV抗体,狂犬病毒中和抗体(VNA)在接种后14天达保护水平>0.5 IU/ml,30天达峰值24.5±10.23 IU/ml;接种猫无FHV-1感染临床症状,且狂犬病攻毒后存活,而对照猫出现严重鼻气管炎并死于狂犬病。
要点
- FHV-RVG重组疫苗可诱导猫产生抗FHV-1和RABV抗体。
- 接种后14天狂犬VNA>0.5 IU/ml,30天峰值24.5±10.23 IU/ml。
- 接种猫耐受FHV-1和RABV攻毒,对照猫发病死亡。
核心结论
- FHV-RVG重组疫苗在猫中对FHV-1和RABV感染均具有保护效果。
研究设计与样本
- 构建缺失gI/E并插入RABV BD06株G基因的FHV-1重组病毒FHV-RVG。
- 猫经鼻接种1 ml 10^6.5 TCID50 FHV-RVG,定期采血测抗体。
- 接种完成后第180天和第194天分别进行疱疹病毒和狂犬病病毒攻毒。
主要发现
- 所有接种猫均产生抗FHV-1和RABV抗体。
- 狂犬VNA在接种后14天达>0.5 IU/ml,30天峰值24.5±10.23 IU/ml。
- 接种猫无FHV-1感染临床症状,狂犬病攻毒后存活。
- 对照猫出现严重鼻气管炎并死于狂犬病。
关键数值与推荐
- 猫经鼻接种剂量为1 ml 10^6.5 TCID50 FHV-RVG。
- 狂犬VNA保护阈值采用>0.5 IU/ml。
- 接种后14天VNA>0.5 IU/ml,30天VNA 24.5±10.23 IU/ml。
临床怎么用
- 该疫苗候选可同时预防猫FHV-1感染和狂犬病,支持后续临床开发。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In China, cats cause about 5% of human rabies cases. Rabies control in cats plays a role in achieving the ultimate goal of elimination of dog rabies-mediated human deaths. However, there is no cat-specific rabies vaccine in China yet. In this study, we constructed a recombinant rabies vaccine by using a felid herpesvirus 1 (FHV-1) isolate, and deleted the gI/E in the FHV-1 and replaced the region with a glycoprotein (G) of rabies virus (RABV) strain BD06 through homologous recombination. The recombinant virus FHV-RVG was recovered and purified, and the expression of RABV glycoprotein was verified by indirect immunofluorescent assay. For potency in cats, each animal was inoculated intranasally with 1 ml FHV-RVG at 106.5 TCID50. Blood samples were collected at defined intervals for antibody titration. The animals were challenged by herpes and rabies after completion of vaccination on day 180 and day 194, respectively. Our results demonstrated all vaccinated cats generated antibodies against both FHV-1 and RABV, and reached an arbitrary protective titer > 0.5 IU/ml for rabies viral neutralizing antibody (VNA) by day 14 post inoculation (dpi) and titer peaked on 30 dpi with VNA at 24.5 ± 10.23 IU/ml. All vaccinated cats presented no clinical signs of FHV-1 infection and survived rabies challenge, while the control cats had severe rhinotracheitis and died from rabies after challenge. All this demonstrated that the FHV-based recombinant vaccine is effective in protection against both FHV-1 and RABV infections.
引用
- Chen T, Zhou X, Qi Y, et al. Feline herpesvirus vectored-rabies vaccine in cats: A dual protection. Vaccine. 2019. PMID: 30878247. doi:10.1016/j.vaccine.2019.03.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。